nodes	percent_of_prediction	percent_of_DWPC	metapath
Triazolam—CYP3A4—bone cancer	0.844	1	CbGaD
Triazolam—Slurred speech—Cisplatin—bone cancer	0.00375	0.0381	CcSEcCtD
Triazolam—Dysaesthesia—Epirubicin—bone cancer	0.00199	0.0202	CcSEcCtD
Triazolam—Dysaesthesia—Doxorubicin—bone cancer	0.00184	0.0187	CcSEcCtD
Triazolam—Dysarthria—Cisplatin—bone cancer	0.00178	0.018	CcSEcCtD
Triazolam—Hearing impaired—Cisplatin—bone cancer	0.00176	0.0179	CcSEcCtD
Triazolam—Pain—Carboplatin—bone cancer	0.00175	0.0177	CcSEcCtD
Triazolam—CYP3A7—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00158	0.0324	CbGpPWpGaD
Triazolam—Deafness—Cisplatin—bone cancer	0.00136	0.0138	CcSEcCtD
Triazolam—Amnesia—Cisplatin—bone cancer	0.0013	0.0132	CcSEcCtD
Triazolam—Redness—Epirubicin—bone cancer	0.00128	0.013	CcSEcCtD
Triazolam—Redness—Doxorubicin—bone cancer	0.00118	0.012	CcSEcCtD
Triazolam—Irritability—Cisplatin—bone cancer	0.00116	0.0118	CcSEcCtD
Triazolam—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00114	0.0234	CbGpPWpGaD
Triazolam—Cramp muscle—Cisplatin—bone cancer	0.0011	0.0111	CcSEcCtD
Triazolam—Sweating increased—Cisplatin—bone cancer	0.00103	0.0104	CcSEcCtD
Triazolam—Glossitis—Methotrexate—bone cancer	0.001	0.0101	CcSEcCtD
Triazolam—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000991	0.0203	CbGpPWpGaD
Triazolam—Dysarthria—Methotrexate—bone cancer	0.000974	0.00988	CcSEcCtD
Triazolam—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000947	0.0194	CbGpPWpGaD
Triazolam—Thinking abnormal—Epirubicin—bone cancer	0.000942	0.00955	CcSEcCtD
Triazolam—Glossitis—Epirubicin—bone cancer	0.000936	0.00949	CcSEcCtD
Triazolam—Stomatitis—Cisplatin—bone cancer	0.000915	0.00928	CcSEcCtD
Triazolam—Dysarthria—Epirubicin—bone cancer	0.000912	0.00924	CcSEcCtD
Triazolam—Depressed level of consciousness—Methotrexate—bone cancer	0.00089	0.00902	CcSEcCtD
Triazolam—Coordination abnormal—Epirubicin—bone cancer	0.000878	0.0089	CcSEcCtD
Triazolam—Thinking abnormal—Doxorubicin—bone cancer	0.000871	0.00884	CcSEcCtD
Triazolam—Glossitis—Doxorubicin—bone cancer	0.000866	0.00878	CcSEcCtD
Triazolam—Dysarthria—Doxorubicin—bone cancer	0.000843	0.00855	CcSEcCtD
Triazolam—GABRQ—Orphan transporters—TUBB4B—bone cancer	0.000842	0.0172	CbGpPWpGaD
Triazolam—GABRR2—Mecp2 and Associated Rett Syndrome—EZH2—bone cancer	0.000817	0.0167	CbGpPWpGaD
Triazolam—Visual impairment—Cisplatin—bone cancer	0.000812	0.00824	CcSEcCtD
Triazolam—Coordination abnormal—Doxorubicin—bone cancer	0.000812	0.00824	CcSEcCtD
Triazolam—GABRA1—SIDS Susceptibility Pathways—FEV—bone cancer	0.000812	0.0166	CbGpPWpGaD
Triazolam—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000806	0.0165	CbGpPWpGaD
Triazolam—Tinnitus—Cisplatin—bone cancer	0.000786	0.00797	CcSEcCtD
Triazolam—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000771	0.0158	CbGpPWpGaD
Triazolam—Chlordiazepoxide—CYP3A4—bone cancer	0.000769	0.0899	CrCbGaD
Triazolam—CYP3A7—Xenobiotics—CYP3A4—bone cancer	0.000764	0.0156	CbGpPWpGaD
Triazolam—Mental disability—Epirubicin—bone cancer	0.000748	0.00759	CcSEcCtD
Triazolam—Hepatic failure—Methotrexate—bone cancer	0.000744	0.00755	CcSEcCtD
Triazolam—Clonazepam—CYP3A4—bone cancer	0.000743	0.0868	CrCbGaD
Triazolam—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000734	0.015	CbGpPWpGaD
Triazolam—Erythema—Cisplatin—bone cancer	0.000734	0.00744	CcSEcCtD
Triazolam—GABRQ—Orphan transporters—TUBB2A—bone cancer	0.000726	0.0149	CbGpPWpGaD
Triazolam—Flatulence—Cisplatin—bone cancer	0.000723	0.00733	CcSEcCtD
Triazolam—Visual disturbance—Methotrexate—bone cancer	0.000706	0.00716	CcSEcCtD
Triazolam—Muscle spasms—Cisplatin—bone cancer	0.000706	0.00716	CcSEcCtD
Triazolam—Hepatic failure—Epirubicin—bone cancer	0.000696	0.00706	CcSEcCtD
Triazolam—GABRG3—Orphan transporters—TUBB4B—bone cancer	0.000693	0.0142	CbGpPWpGaD
Triazolam—Mental disability—Doxorubicin—bone cancer	0.000692	0.00702	CcSEcCtD
Triazolam—Clotiazepam—CYP3A4—bone cancer	0.00069	0.0806	CrCbGaD
Triazolam—Tremor—Cisplatin—bone cancer	0.000688	0.00697	CcSEcCtD
Triazolam—GABRB1—Orphan transporters—TUBB4B—bone cancer	0.000683	0.014	CbGpPWpGaD
Triazolam—CYP3A7—Metapathway biotransformation—CYP4V2—bone cancer	0.000681	0.0139	CbGpPWpGaD
Triazolam—Ill-defined disorder—Cisplatin—bone cancer	0.000681	0.00691	CcSEcCtD
Triazolam—Osteoarthritis—Methotrexate—bone cancer	0.000669	0.00678	CcSEcCtD
Triazolam—Malaise—Cisplatin—bone cancer	0.000662	0.00671	CcSEcCtD
Triazolam—Alprazolam—CYP3A4—bone cancer	0.000651	0.0761	CrCbGaD
Triazolam—Clobazam—CYP3A4—bone cancer	0.000651	0.0761	CrCbGaD
Triazolam—GABRA6—Orphan transporters—TUBB4B—bone cancer	0.000646	0.0132	CbGpPWpGaD
Triazolam—Hepatic failure—Doxorubicin—bone cancer	0.000644	0.00653	CcSEcCtD
Triazolam—Irritability—Methotrexate—bone cancer	0.000638	0.00647	CcSEcCtD
Triazolam—GABRA4—Orphan transporters—TUBB4B—bone cancer	0.000638	0.0131	CbGpPWpGaD
Triazolam—Mood swings—Methotrexate—bone cancer	0.000634	0.00642	CcSEcCtD
Triazolam—Quazepam—CYP3A4—bone cancer	0.000632	0.0738	CrCbGaD
Triazolam—Ataxia—Methotrexate—bone cancer	0.000629	0.00638	CcSEcCtD
Triazolam—Osteoarthritis—Epirubicin—bone cancer	0.000626	0.00635	CcSEcCtD
Triazolam—Anxiety—Cisplatin—bone cancer	0.000623	0.00631	CcSEcCtD
Triazolam—Discomfort—Cisplatin—bone cancer	0.000617	0.00626	CcSEcCtD
Triazolam—Affect lability—Epirubicin—bone cancer	0.000616	0.00625	CcSEcCtD
Triazolam—Oedema—Cisplatin—bone cancer	0.000599	0.00607	CcSEcCtD
Triazolam—GABRG3—Orphan transporters—TUBB2A—bone cancer	0.000598	0.0123	CbGpPWpGaD
Triazolam—Flunitrazepam—CYP3A4—bone cancer	0.000596	0.0697	CrCbGaD
Triazolam—Mood swings—Epirubicin—bone cancer	0.000593	0.00601	CcSEcCtD
Triazolam—GABRB1—Orphan transporters—TUBB2A—bone cancer	0.000589	0.0121	CbGpPWpGaD
Triazolam—Ataxia—Epirubicin—bone cancer	0.000588	0.00597	CcSEcCtD
Triazolam—Tachycardia—Cisplatin—bone cancer	0.000585	0.00593	CcSEcCtD
Triazolam—GABRB2—Orphan transporters—TUBB4B—bone cancer	0.000583	0.0119	CbGpPWpGaD
Triazolam—Osteoarthritis—Doxorubicin—bone cancer	0.000579	0.00587	CcSEcCtD
Triazolam—Hyperhidrosis—Cisplatin—bone cancer	0.000579	0.00587	CcSEcCtD
Triazolam—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000575	0.0118	CbGpPWpGaD
Triazolam—Anorexia—Cisplatin—bone cancer	0.000571	0.00579	CcSEcCtD
Triazolam—Affect lability—Doxorubicin—bone cancer	0.00057	0.00578	CcSEcCtD
Triazolam—GABRA5—Orphan transporters—TUBB4B—bone cancer	0.000567	0.0116	CbGpPWpGaD
Triazolam—Estazolam—CYP3A4—bone cancer	0.000558	0.0652	CrCbGaD
Triazolam—GABRA6—Orphan transporters—TUBB2A—bone cancer	0.000558	0.0114	CbGpPWpGaD
Triazolam—GABRA3—Orphan transporters—TUBB4B—bone cancer	0.000556	0.0114	CbGpPWpGaD
Triazolam—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000552	0.0113	CbGpPWpGaD
Triazolam—Muscular weakness—Epirubicin—bone cancer	0.000552	0.0056	CcSEcCtD
Triazolam—GABRA4—Orphan transporters—TUBB2A—bone cancer	0.000551	0.0113	CbGpPWpGaD
Triazolam—Mood swings—Doxorubicin—bone cancer	0.000549	0.00556	CcSEcCtD
Triazolam—GABRA2—Orphan transporters—TUBB4B—bone cancer	0.000547	0.0112	CbGpPWpGaD
Triazolam—Ataxia—Doxorubicin—bone cancer	0.000545	0.00552	CcSEcCtD
Triazolam—GABRB3—Orphan transporters—TUBB4B—bone cancer	0.000543	0.0111	CbGpPWpGaD
Triazolam—Dysuria—Methotrexate—bone cancer	0.00054	0.00548	CcSEcCtD
Triazolam—Paraesthesia—Cisplatin—bone cancer	0.000538	0.00545	CcSEcCtD
Triazolam—Dyspnoea—Cisplatin—bone cancer	0.000534	0.00542	CcSEcCtD
Triazolam—GABRG2—Orphan transporters—TUBB4B—bone cancer	0.000534	0.0109	CbGpPWpGaD
Triazolam—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000532	0.0109	CbGpPWpGaD
Triazolam—Adinazolam—CYP3A4—bone cancer	0.000531	0.062	CrCbGaD
Triazolam—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000531	0.0109	CbGpPWpGaD
Triazolam—Decreased appetite—Cisplatin—bone cancer	0.000521	0.00528	CcSEcCtD
Triazolam—Drowsiness—Methotrexate—bone cancer	0.000515	0.00523	CcSEcCtD
Triazolam—Prazepam—CYP3A4—bone cancer	0.000513	0.06	CrCbGaD
Triazolam—Pain—Cisplatin—bone cancer	0.000512	0.00519	CcSEcCtD
Triazolam—Muscular weakness—Doxorubicin—bone cancer	0.000511	0.00518	CcSEcCtD
Triazolam—Dysuria—Epirubicin—bone cancer	0.000506	0.00513	CcSEcCtD
Triazolam—GABRB2—Orphan transporters—TUBB2A—bone cancer	0.000504	0.0103	CbGpPWpGaD
Triazolam—Stomatitis—Methotrexate—bone cancer	0.000502	0.00509	CcSEcCtD
Triazolam—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.0005	0.0102	CbGpPWpGaD
Triazolam—Feeling abnormal—Cisplatin—bone cancer	0.000494	0.00501	CcSEcCtD
Triazolam—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000492	0.0101	CbGpPWpGaD
Triazolam—GABRA5—Orphan transporters—TUBB2A—bone cancer	0.000489	0.01	CbGpPWpGaD
Triazolam—Drowsiness—Epirubicin—bone cancer	0.000482	0.00489	CcSEcCtD
Triazolam—GABRA3—Orphan transporters—TUBB2A—bone cancer	0.00048	0.00984	CbGpPWpGaD
Triazolam—Flurazepam—CYP3A4—bone cancer	0.000479	0.0559	CrCbGaD
Triazolam—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000478	0.00979	CbGpPWpGaD
Triazolam—GABRA2—Orphan transporters—TUBB2A—bone cancer	0.000472	0.00967	CbGpPWpGaD
Triazolam—Stomatitis—Epirubicin—bone cancer	0.00047	0.00477	CcSEcCtD
Triazolam—Jaundice—Epirubicin—bone cancer	0.00047	0.00477	CcSEcCtD
Triazolam—GABRB3—Orphan transporters—TUBB2A—bone cancer	0.000469	0.0096	CbGpPWpGaD
Triazolam—Dysuria—Doxorubicin—bone cancer	0.000468	0.00475	CcSEcCtD
Triazolam—GABRA1—Orphan transporters—TUBB4B—bone cancer	0.000466	0.00955	CbGpPWpGaD
Triazolam—Oxazepam—CYP3A4—bone cancer	0.000464	0.0542	CrCbGaD
Triazolam—GABRG2—Orphan transporters—TUBB2A—bone cancer	0.000461	0.00943	CbGpPWpGaD
Triazolam—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.00046	0.00942	CbGpPWpGaD
Triazolam—Temazepam—CYP3A4—bone cancer	0.000458	0.0535	CrCbGaD
Triazolam—Drowsiness—Doxorubicin—bone cancer	0.000446	0.00453	CcSEcCtD
Triazolam—Visual impairment—Methotrexate—bone cancer	0.000446	0.00452	CcSEcCtD
Triazolam—Midazolam—CYP3A4—bone cancer	0.000444	0.0519	CrCbGaD
Triazolam—Hypersensitivity—Cisplatin—bone cancer	0.000441	0.00448	CcSEcCtD
Triazolam—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000436	0.00892	CbGpPWpGaD
Triazolam—Jaundice—Doxorubicin—bone cancer	0.000435	0.00441	CcSEcCtD
Triazolam—Stomatitis—Doxorubicin—bone cancer	0.000435	0.00441	CcSEcCtD
Triazolam—Tinnitus—Methotrexate—bone cancer	0.000431	0.00437	CcSEcCtD
Triazolam—Asthenia—Cisplatin—bone cancer	0.00043	0.00436	CcSEcCtD
Triazolam—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000426	0.00873	CbGpPWpGaD
Triazolam—Visual impairment—Epirubicin—bone cancer	0.000417	0.00423	CcSEcCtD
Triazolam—Diarrhoea—Cisplatin—bone cancer	0.00041	0.00416	CcSEcCtD
Triazolam—Tinnitus—Epirubicin—bone cancer	0.000404	0.00409	CcSEcCtD
Triazolam—Erythema—Methotrexate—bone cancer	0.000403	0.00408	CcSEcCtD
Triazolam—GABRA1—Orphan transporters—TUBB2A—bone cancer	0.000403	0.00824	CbGpPWpGaD
Triazolam—Dysgeusia—Methotrexate—bone cancer	0.000394	0.004	CcSEcCtD
Triazolam—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000389	0.00797	CbGpPWpGaD
Triazolam—Visual impairment—Doxorubicin—bone cancer	0.000386	0.00392	CcSEcCtD
Triazolam—Vomiting—Cisplatin—bone cancer	0.000381	0.00386	CcSEcCtD
Triazolam—Diazepam—CYP3A4—bone cancer	0.00038	0.0444	CrCbGaD
Triazolam—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000379	0.00776	CbGpPWpGaD
Triazolam—Dermatitis—Cisplatin—bone cancer	0.000377	0.00383	CcSEcCtD
Triazolam—Erythema—Epirubicin—bone cancer	0.000377	0.00382	CcSEcCtD
Triazolam—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000374	0.00766	CbGpPWpGaD
Triazolam—Ill-defined disorder—Methotrexate—bone cancer	0.000374	0.00379	CcSEcCtD
Triazolam—Tinnitus—Doxorubicin—bone cancer	0.000374	0.00379	CcSEcCtD
Triazolam—Flatulence—Epirubicin—bone cancer	0.000371	0.00377	CcSEcCtD
Triazolam—Tension—Epirubicin—bone cancer	0.00037	0.00375	CcSEcCtD
Triazolam—Dysgeusia—Epirubicin—bone cancer	0.000369	0.00374	CcSEcCtD
Triazolam—Nervousness—Epirubicin—bone cancer	0.000366	0.00371	CcSEcCtD
Triazolam—Malaise—Methotrexate—bone cancer	0.000363	0.00368	CcSEcCtD
Triazolam—Muscle spasms—Epirubicin—bone cancer	0.000362	0.00367	CcSEcCtD
Triazolam—Nausea—Cisplatin—bone cancer	0.000356	0.00361	CcSEcCtD
Triazolam—Ill-defined disorder—Epirubicin—bone cancer	0.00035	0.00355	CcSEcCtD
Triazolam—Erythema—Doxorubicin—bone cancer	0.000349	0.00354	CcSEcCtD
Triazolam—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000347	0.00711	CbGpPWpGaD
Triazolam—Agitation—Epirubicin—bone cancer	0.000346	0.00351	CcSEcCtD
Triazolam—Flatulence—Doxorubicin—bone cancer	0.000344	0.00348	CcSEcCtD
Triazolam—Chest pain—Methotrexate—bone cancer	0.000343	0.00348	CcSEcCtD
Triazolam—Tension—Doxorubicin—bone cancer	0.000342	0.00347	CcSEcCtD
Triazolam—Dysgeusia—Doxorubicin—bone cancer	0.000342	0.00346	CcSEcCtD
Triazolam—Malaise—Epirubicin—bone cancer	0.00034	0.00345	CcSEcCtD
Triazolam—Discomfort—Methotrexate—bone cancer	0.000339	0.00344	CcSEcCtD
Triazolam—Nervousness—Doxorubicin—bone cancer	0.000339	0.00343	CcSEcCtD
Triazolam—Syncope—Epirubicin—bone cancer	0.000338	0.00343	CcSEcCtD
Triazolam—Muscle spasms—Doxorubicin—bone cancer	0.000335	0.0034	CcSEcCtD
Triazolam—Palpitations—Epirubicin—bone cancer	0.000333	0.00338	CcSEcCtD
Triazolam—Confusional state—Methotrexate—bone cancer	0.000331	0.00336	CcSEcCtD
Triazolam—Loss of consciousness—Epirubicin—bone cancer	0.000331	0.00336	CcSEcCtD
Triazolam—Hypertension—Epirubicin—bone cancer	0.000325	0.0033	CcSEcCtD
Triazolam—Ill-defined disorder—Doxorubicin—bone cancer	0.000324	0.00328	CcSEcCtD
Triazolam—Chest pain—Epirubicin—bone cancer	0.000321	0.00325	CcSEcCtD
Triazolam—Agitation—Doxorubicin—bone cancer	0.00032	0.00325	CcSEcCtD
Triazolam—Anxiety—Epirubicin—bone cancer	0.00032	0.00324	CcSEcCtD
Triazolam—Hyperhidrosis—Methotrexate—bone cancer	0.000318	0.00322	CcSEcCtD
Triazolam—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000317	0.00649	CbGpPWpGaD
Triazolam—Discomfort—Epirubicin—bone cancer	0.000317	0.00322	CcSEcCtD
Triazolam—Malaise—Doxorubicin—bone cancer	0.000314	0.00319	CcSEcCtD
Triazolam—Dry mouth—Epirubicin—bone cancer	0.000314	0.00318	CcSEcCtD
Triazolam—Anorexia—Methotrexate—bone cancer	0.000313	0.00318	CcSEcCtD
Triazolam—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000313	0.00641	CbGpPWpGaD
Triazolam—Syncope—Doxorubicin—bone cancer	0.000313	0.00317	CcSEcCtD
Triazolam—Confusional state—Epirubicin—bone cancer	0.00031	0.00315	CcSEcCtD
Triazolam—Palpitations—Doxorubicin—bone cancer	0.000308	0.00313	CcSEcCtD
Triazolam—Oedema—Epirubicin—bone cancer	0.000308	0.00312	CcSEcCtD
Triazolam—Loss of consciousness—Doxorubicin—bone cancer	0.000307	0.00311	CcSEcCtD
Triazolam—Shock—Epirubicin—bone cancer	0.000303	0.00307	CcSEcCtD
Triazolam—Hypertension—Doxorubicin—bone cancer	0.000301	0.00305	CcSEcCtD
Triazolam—Tachycardia—Epirubicin—bone cancer	0.0003	0.00304	CcSEcCtD
Triazolam—Hyperhidrosis—Epirubicin—bone cancer	0.000297	0.00302	CcSEcCtD
Triazolam—Insomnia—Methotrexate—bone cancer	0.000297	0.00301	CcSEcCtD
Triazolam—Chest pain—Doxorubicin—bone cancer	0.000297	0.00301	CcSEcCtD
Triazolam—Anxiety—Doxorubicin—bone cancer	0.000296	0.003	CcSEcCtD
Triazolam—Paraesthesia—Methotrexate—bone cancer	0.000295	0.00299	CcSEcCtD
Triazolam—Discomfort—Doxorubicin—bone cancer	0.000293	0.00297	CcSEcCtD
Triazolam—Anorexia—Epirubicin—bone cancer	0.000293	0.00297	CcSEcCtD
Triazolam—Dyspnoea—Methotrexate—bone cancer	0.000293	0.00297	CcSEcCtD
Triazolam—Somnolence—Methotrexate—bone cancer	0.000292	0.00296	CcSEcCtD
Triazolam—Dry mouth—Doxorubicin—bone cancer	0.00029	0.00294	CcSEcCtD
Triazolam—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000287	0.00588	CbGpPWpGaD
Triazolam—Confusional state—Doxorubicin—bone cancer	0.000287	0.00291	CcSEcCtD
Triazolam—Decreased appetite—Methotrexate—bone cancer	0.000286	0.0029	CcSEcCtD
Triazolam—Oedema—Doxorubicin—bone cancer	0.000285	0.00289	CcSEcCtD
Triazolam—Fatigue—Methotrexate—bone cancer	0.000283	0.00287	CcSEcCtD
Triazolam—Pain—Methotrexate—bone cancer	0.000281	0.00285	CcSEcCtD
Triazolam—Shock—Doxorubicin—bone cancer	0.00028	0.00284	CcSEcCtD
Triazolam—Insomnia—Epirubicin—bone cancer	0.000278	0.00282	CcSEcCtD
Triazolam—Tachycardia—Doxorubicin—bone cancer	0.000278	0.00282	CcSEcCtD
Triazolam—Paraesthesia—Epirubicin—bone cancer	0.000276	0.0028	CcSEcCtD
Triazolam—Hyperhidrosis—Doxorubicin—bone cancer	0.000275	0.00279	CcSEcCtD
Triazolam—Dyspnoea—Epirubicin—bone cancer	0.000274	0.00278	CcSEcCtD
Triazolam—Somnolence—Epirubicin—bone cancer	0.000273	0.00277	CcSEcCtD
Triazolam—Anorexia—Doxorubicin—bone cancer	0.000271	0.00275	CcSEcCtD
Triazolam—Feeling abnormal—Methotrexate—bone cancer	0.000271	0.00275	CcSEcCtD
Triazolam—Gastrointestinal pain—Methotrexate—bone cancer	0.000269	0.00273	CcSEcCtD
Triazolam—Decreased appetite—Epirubicin—bone cancer	0.000267	0.00271	CcSEcCtD
Triazolam—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000267	0.00547	CbGpPWpGaD
Triazolam—Fatigue—Epirubicin—bone cancer	0.000265	0.00269	CcSEcCtD
Triazolam—Constipation—Epirubicin—bone cancer	0.000263	0.00267	CcSEcCtD
Triazolam—Pain—Epirubicin—bone cancer	0.000263	0.00267	CcSEcCtD
Triazolam—Abdominal pain—Methotrexate—bone cancer	0.00026	0.00264	CcSEcCtD
Triazolam—Insomnia—Doxorubicin—bone cancer	0.000257	0.00261	CcSEcCtD
Triazolam—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000257	0.00526	CbGpPWpGaD
Triazolam—Paraesthesia—Doxorubicin—bone cancer	0.000256	0.00259	CcSEcCtD
Triazolam—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000255	0.00521	CbGpPWpGaD
Triazolam—Dyspnoea—Doxorubicin—bone cancer	0.000254	0.00257	CcSEcCtD
Triazolam—Feeling abnormal—Epirubicin—bone cancer	0.000253	0.00257	CcSEcCtD
Triazolam—Somnolence—Doxorubicin—bone cancer	0.000253	0.00257	CcSEcCtD
Triazolam—GABRB3—BDNF signaling pathway—EIF2S1—bone cancer	0.000252	0.00516	CbGpPWpGaD
Triazolam—Gastrointestinal pain—Epirubicin—bone cancer	0.000252	0.00255	CcSEcCtD
Triazolam—Decreased appetite—Doxorubicin—bone cancer	0.000247	0.00251	CcSEcCtD
Triazolam—Fatigue—Doxorubicin—bone cancer	0.000245	0.00249	CcSEcCtD
Triazolam—Constipation—Doxorubicin—bone cancer	0.000243	0.00247	CcSEcCtD
Triazolam—Pain—Doxorubicin—bone cancer	0.000243	0.00247	CcSEcCtD
Triazolam—Abdominal pain—Epirubicin—bone cancer	0.000243	0.00247	CcSEcCtD
Triazolam—Hypersensitivity—Methotrexate—bone cancer	0.000242	0.00246	CcSEcCtD
Triazolam—Asthenia—Methotrexate—bone cancer	0.000236	0.00239	CcSEcCtD
Triazolam—Feeling abnormal—Doxorubicin—bone cancer	0.000235	0.00238	CcSEcCtD
Triazolam—Gastrointestinal pain—Doxorubicin—bone cancer	0.000233	0.00236	CcSEcCtD
Triazolam—Pruritus—Methotrexate—bone cancer	0.000233	0.00236	CcSEcCtD
Triazolam—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000229	0.00469	CbGpPWpGaD
Triazolam—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000229	0.00469	CbGpPWpGaD
Triazolam—Hypersensitivity—Epirubicin—bone cancer	0.000227	0.0023	CcSEcCtD
Triazolam—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000226	0.00463	CbGpPWpGaD
Triazolam—Abdominal pain—Doxorubicin—bone cancer	0.000225	0.00228	CcSEcCtD
Triazolam—Diarrhoea—Methotrexate—bone cancer	0.000225	0.00228	CcSEcCtD
Triazolam—Asthenia—Epirubicin—bone cancer	0.000221	0.00224	CcSEcCtD
Triazolam—Pruritus—Epirubicin—bone cancer	0.000218	0.00221	CcSEcCtD
Triazolam—Dizziness—Methotrexate—bone cancer	0.000217	0.0022	CcSEcCtD
Triazolam—GABRR1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000215	0.00441	CbGpPWpGaD
Triazolam—Diarrhoea—Epirubicin—bone cancer	0.00021	0.00213	CcSEcCtD
Triazolam—Hypersensitivity—Doxorubicin—bone cancer	0.00021	0.00213	CcSEcCtD
Triazolam—Vomiting—Methotrexate—bone cancer	0.000209	0.00212	CcSEcCtD
Triazolam—Dermatitis—Methotrexate—bone cancer	0.000207	0.0021	CcSEcCtD
Triazolam—Headache—Methotrexate—bone cancer	0.000206	0.00209	CcSEcCtD
Triazolam—GABRQ—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000205	0.00421	CbGpPWpGaD
Triazolam—GABRR2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000205	0.00421	CbGpPWpGaD
Triazolam—Asthenia—Doxorubicin—bone cancer	0.000204	0.00207	CcSEcCtD
Triazolam—Dizziness—Epirubicin—bone cancer	0.000203	0.00206	CcSEcCtD
Triazolam—Pruritus—Doxorubicin—bone cancer	0.000201	0.00204	CcSEcCtD
Triazolam—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000199	0.00407	CbGpPWpGaD
Triazolam—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000196	0.00401	CbGpPWpGaD
Triazolam—Vomiting—Epirubicin—bone cancer	0.000196	0.00198	CcSEcCtD
Triazolam—Nausea—Methotrexate—bone cancer	0.000195	0.00198	CcSEcCtD
Triazolam—Diarrhoea—Doxorubicin—bone cancer	0.000195	0.00197	CcSEcCtD
Triazolam—Dermatitis—Epirubicin—bone cancer	0.000194	0.00197	CcSEcCtD
Triazolam—Headache—Epirubicin—bone cancer	0.000193	0.00195	CcSEcCtD
Triazolam—Dizziness—Doxorubicin—bone cancer	0.000188	0.00191	CcSEcCtD
Triazolam—GABRR1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000186	0.00381	CbGpPWpGaD
Triazolam—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000186	0.00381	CbGpPWpGaD
Triazolam—Nausea—Epirubicin—bone cancer	0.000183	0.00185	CcSEcCtD
Triazolam—GABRR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000182	0.00372	CbGpPWpGaD
Triazolam—Vomiting—Doxorubicin—bone cancer	0.000181	0.00184	CcSEcCtD
Triazolam—Dermatitis—Doxorubicin—bone cancer	0.000179	0.00182	CcSEcCtD
Triazolam—Headache—Doxorubicin—bone cancer	0.000178	0.00181	CcSEcCtD
Triazolam—GABRQ—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000177	0.00363	CbGpPWpGaD
Triazolam—GABRR2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000177	0.00363	CbGpPWpGaD
Triazolam—GABRR2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000173	0.00355	CbGpPWpGaD
Triazolam—GABRQ—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000173	0.00355	CbGpPWpGaD
Triazolam—GABRG3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000169	0.00346	CbGpPWpGaD
Triazolam—Nausea—Doxorubicin—bone cancer	0.000169	0.00171	CcSEcCtD
Triazolam—GABRB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000167	0.00341	CbGpPWpGaD
Triazolam—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000162	0.00331	CbGpPWpGaD
Triazolam—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000161	0.0033	CbGpPWpGaD
Triazolam—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000159	0.00327	CbGpPWpGaD
Triazolam—GABRA6—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000158	0.00323	CbGpPWpGaD
Triazolam—GABRA4—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000156	0.00319	CbGpPWpGaD
Triazolam—GABRR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000152	0.00312	CbGpPWpGaD
Triazolam—GABRG3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000146	0.00299	CbGpPWpGaD
Triazolam—GABRR2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000145	0.00297	CbGpPWpGaD
Triazolam—GABRQ—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000145	0.00297	CbGpPWpGaD
Triazolam—GABRB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000144	0.00295	CbGpPWpGaD
Triazolam—GABRG3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000143	0.00292	CbGpPWpGaD
Triazolam—GABRB2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000142	0.00292	CbGpPWpGaD
Triazolam—GABRB1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000141	0.00288	CbGpPWpGaD
Triazolam—GABRA5—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000138	0.00283	CbGpPWpGaD
Triazolam—GABRR1—Transmission across Chemical Synapses—BRAF—bone cancer	0.000137	0.0028	CbGpPWpGaD
Triazolam—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000137	0.0028	CbGpPWpGaD
Triazolam—GABRA6—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000136	0.00279	CbGpPWpGaD
Triazolam—GABRA3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000136	0.00278	CbGpPWpGaD
Triazolam—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000135	0.00276	CbGpPWpGaD
Triazolam—GABRA4—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000134	0.00275	CbGpPWpGaD
Triazolam—GABRA2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000134	0.00273	CbGpPWpGaD
Triazolam—GABRA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000133	0.00272	CbGpPWpGaD
Triazolam—GABRB3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000133	0.00272	CbGpPWpGaD
Triazolam—GABRA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000131	0.00269	CbGpPWpGaD
Triazolam—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000131	0.00268	CbGpPWpGaD
Triazolam—GABRQ—Transmission across Chemical Synapses—BRAF—bone cancer	0.00013	0.00267	CbGpPWpGaD
Triazolam—GABRR2—Transmission across Chemical Synapses—BRAF—bone cancer	0.00013	0.00267	CbGpPWpGaD
Triazolam—GABRG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00013	0.00267	CbGpPWpGaD
Triazolam—GABRB2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000123	0.00252	CbGpPWpGaD
Triazolam—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.00012	0.00246	CbGpPWpGaD
Triazolam—GABRG3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.00012	0.00245	CbGpPWpGaD
Triazolam—GABRA5—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000119	0.00245	CbGpPWpGaD
Triazolam—GABRB1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000118	0.00241	CbGpPWpGaD
Triazolam—GABRA3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000117	0.0024	CbGpPWpGaD
Triazolam—CYP3A7—Biological oxidations—GSTP1—bone cancer	0.000117	0.00239	CbGpPWpGaD
Triazolam—GABRA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000117	0.00239	CbGpPWpGaD
Triazolam—GABRA2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000115	0.00236	CbGpPWpGaD
Triazolam—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	0.000115	0.00236	CbGpPWpGaD
Triazolam—GABRA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000115	0.00235	CbGpPWpGaD
Triazolam—GABRB3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000114	0.00234	CbGpPWpGaD
Triazolam—GABRR1—Transmission across Chemical Synapses—MDM2—bone cancer	0.000114	0.00234	CbGpPWpGaD
Triazolam—GABRA1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000114	0.00233	CbGpPWpGaD
Triazolam—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000113	0.00231	CbGpPWpGaD
Triazolam—GABRG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000112	0.0023	CbGpPWpGaD
Triazolam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000112	0.00229	CbGpPWpGaD
Triazolam—GABRA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000111	0.00228	CbGpPWpGaD
Triazolam—GABRA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.00011	0.00225	CbGpPWpGaD
Triazolam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.00011	0.00225	CbGpPWpGaD
Triazolam—GABRR2—Transmission across Chemical Synapses—MDM2—bone cancer	0.000109	0.00224	CbGpPWpGaD
Triazolam—GABRQ—Transmission across Chemical Synapses—MDM2—bone cancer	0.000109	0.00224	CbGpPWpGaD
Triazolam—GABRG3—Transmission across Chemical Synapses—BRAF—bone cancer	0.000107	0.0022	CbGpPWpGaD
Triazolam—GABRB1—Transmission across Chemical Synapses—BRAF—bone cancer	0.000106	0.00216	CbGpPWpGaD
Triazolam—GABRR1—Neuronal System—BRAF—bone cancer	0.000105	0.00214	CbGpPWpGaD
Triazolam—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.000102	0.00208	CbGpPWpGaD
Triazolam—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000101	0.00206	CbGpPWpGaD
Triazolam—GABRA6—Transmission across Chemical Synapses—BRAF—bone cancer	0.0001	0.00205	CbGpPWpGaD
Triazolam—GABRR2—Neuronal System—BRAF—bone cancer	9.98e-05	0.00204	CbGpPWpGaD
Triazolam—GABRQ—Neuronal System—BRAF—bone cancer	9.98e-05	0.00204	CbGpPWpGaD
Triazolam—GABRA4—Transmission across Chemical Synapses—BRAF—bone cancer	9.87e-05	0.00202	CbGpPWpGaD
Triazolam—CYP3A5—Biological oxidations—CYP3A4—bone cancer	9.87e-05	0.00202	CbGpPWpGaD
Triazolam—GABRA1—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.83e-05	0.00201	CbGpPWpGaD
Triazolam—GABRA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	9.78e-05	0.002	CbGpPWpGaD
Triazolam—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	9.73e-05	0.00199	CbGpPWpGaD
Triazolam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	9.6e-05	0.00197	CbGpPWpGaD
Triazolam—GABRA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	9.6e-05	0.00197	CbGpPWpGaD
Triazolam—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	9.44e-05	0.00193	CbGpPWpGaD
Triazolam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	9.38e-05	0.00192	CbGpPWpGaD
Triazolam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	9.21e-05	0.00189	CbGpPWpGaD
Triazolam—GABRB2—Transmission across Chemical Synapses—BRAF—bone cancer	9.03e-05	0.00185	CbGpPWpGaD
Triazolam—GABRG3—Transmission across Chemical Synapses—MDM2—bone cancer	8.99e-05	0.00184	CbGpPWpGaD
Triazolam—GABRB1—Transmission across Chemical Synapses—MDM2—bone cancer	8.86e-05	0.00181	CbGpPWpGaD
Triazolam—GABRA5—Transmission across Chemical Synapses—BRAF—bone cancer	8.77e-05	0.0018	CbGpPWpGaD
Triazolam—GABRR1—Neuronal System—MDM2—bone cancer	8.77e-05	0.0018	CbGpPWpGaD
Triazolam—GABRA3—Transmission across Chemical Synapses—BRAF—bone cancer	8.62e-05	0.00176	CbGpPWpGaD
Triazolam—CYP2C8—Biological oxidations—CYP3A4—bone cancer	8.55e-05	0.00175	CbGpPWpGaD
Triazolam—GABRA2—Transmission across Chemical Synapses—BRAF—bone cancer	8.47e-05	0.00173	CbGpPWpGaD
Triazolam—CYP3A5—Biological oxidations—GSTP1—bone cancer	8.44e-05	0.00173	CbGpPWpGaD
Triazolam—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	8.43e-05	0.00173	CbGpPWpGaD
Triazolam—GABRB3—Transmission across Chemical Synapses—BRAF—bone cancer	8.41e-05	0.00172	CbGpPWpGaD
Triazolam—GABRA6—Transmission across Chemical Synapses—MDM2—bone cancer	8.38e-05	0.00172	CbGpPWpGaD
Triazolam—GABRQ—Neuronal System—MDM2—bone cancer	8.36e-05	0.00171	CbGpPWpGaD
Triazolam—GABRR2—Neuronal System—MDM2—bone cancer	8.36e-05	0.00171	CbGpPWpGaD
Triazolam—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	8.33e-05	0.00171	CbGpPWpGaD
Triazolam—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	8.28e-05	0.0017	CbGpPWpGaD
Triazolam—GABRA4—Transmission across Chemical Synapses—MDM2—bone cancer	8.27e-05	0.00169	CbGpPWpGaD
Triazolam—GABRG2—Transmission across Chemical Synapses—BRAF—bone cancer	8.26e-05	0.00169	CbGpPWpGaD
Triazolam—GABRG3—Neuronal System—BRAF—bone cancer	8.22e-05	0.00168	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—NDUFA12—bone cancer	8.18e-05	0.00168	CbGpPWpGaD
Triazolam—GABRB1—Neuronal System—BRAF—bone cancer	8.1e-05	0.00166	CbGpPWpGaD
Triazolam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	8.05e-05	0.00165	CbGpPWpGaD
Triazolam—GABRB3—BDNF signaling pathway—JUN—bone cancer	7.97e-05	0.00163	CbGpPWpGaD
Triazolam—GABRA6—Neuronal System—BRAF—bone cancer	7.66e-05	0.00157	CbGpPWpGaD
Triazolam—GABRB2—Transmission across Chemical Synapses—MDM2—bone cancer	7.57e-05	0.00155	CbGpPWpGaD
Triazolam—GABRA4—Neuronal System—BRAF—bone cancer	7.57e-05	0.00155	CbGpPWpGaD
Triazolam—GABRA5—Transmission across Chemical Synapses—MDM2—bone cancer	7.35e-05	0.00151	CbGpPWpGaD
Triazolam—CYP2C8—Biological oxidations—GSTP1—bone cancer	7.31e-05	0.0015	CbGpPWpGaD
Triazolam—GABRA1—Transmission across Chemical Synapses—BRAF—bone cancer	7.22e-05	0.00148	CbGpPWpGaD
Triazolam—GABRA3—Transmission across Chemical Synapses—MDM2—bone cancer	7.22e-05	0.00148	CbGpPWpGaD
Triazolam—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	7.21e-05	0.00148	CbGpPWpGaD
Triazolam—GABRA2—Transmission across Chemical Synapses—MDM2—bone cancer	7.09e-05	0.00145	CbGpPWpGaD
Triazolam—GABRB3—Transmission across Chemical Synapses—MDM2—bone cancer	7.05e-05	0.00144	CbGpPWpGaD
Triazolam—CYP2C9—Biological oxidations—CYP3A4—bone cancer	6.96e-05	0.00142	CbGpPWpGaD
Triazolam—GABRG2—Transmission across Chemical Synapses—MDM2—bone cancer	6.92e-05	0.00142	CbGpPWpGaD
Triazolam—GABRB2—Neuronal System—BRAF—bone cancer	6.92e-05	0.00142	CbGpPWpGaD
Triazolam—GABRG3—Neuronal System—MDM2—bone cancer	6.89e-05	0.00141	CbGpPWpGaD
Triazolam—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	6.86e-05	0.00141	CbGpPWpGaD
Triazolam—GABRB1—Neuronal System—MDM2—bone cancer	6.78e-05	0.00139	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—NT5C3A—bone cancer	6.78e-05	0.00139	CbGpPWpGaD
Triazolam—GABRA5—Neuronal System—BRAF—bone cancer	6.72e-05	0.00138	CbGpPWpGaD
Triazolam—GABRA3—Neuronal System—BRAF—bone cancer	6.6e-05	0.00135	CbGpPWpGaD
Triazolam—GABRA2—Neuronal System—BRAF—bone cancer	6.49e-05	0.00133	CbGpPWpGaD
Triazolam—GABRB3—Neuronal System—BRAF—bone cancer	6.45e-05	0.00132	CbGpPWpGaD
Triazolam—GABRA6—Neuronal System—MDM2—bone cancer	6.42e-05	0.00131	CbGpPWpGaD
Triazolam—GABRA1—SIDS Susceptibility Pathways—JUN—bone cancer	6.41e-05	0.00131	CbGpPWpGaD
Triazolam—GABRA4—Neuronal System—MDM2—bone cancer	6.34e-05	0.0013	CbGpPWpGaD
Triazolam—GABRG2—Neuronal System—BRAF—bone cancer	6.33e-05	0.0013	CbGpPWpGaD
Triazolam—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	6.06e-05	0.00124	CbGpPWpGaD
Triazolam—GABRA1—Transmission across Chemical Synapses—MDM2—bone cancer	6.05e-05	0.00124	CbGpPWpGaD
Triazolam—CYP2C9—Biological oxidations—GSTP1—bone cancer	5.95e-05	0.00122	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—NDUFA12—bone cancer	5.92e-05	0.00121	CbGpPWpGaD
Triazolam—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	5.87e-05	0.0012	CbGpPWpGaD
Triazolam—GABRB2—Neuronal System—MDM2—bone cancer	5.8e-05	0.00119	CbGpPWpGaD
Triazolam—GABRA5—Neuronal System—MDM2—bone cancer	5.63e-05	0.00115	CbGpPWpGaD
Triazolam—GABRA1—Neuronal System—BRAF—bone cancer	5.53e-05	0.00113	CbGpPWpGaD
Triazolam—GABRA3—Neuronal System—MDM2—bone cancer	5.53e-05	0.00113	CbGpPWpGaD
Triazolam—GABRA2—Neuronal System—MDM2—bone cancer	5.44e-05	0.00111	CbGpPWpGaD
Triazolam—GABRB3—Neuronal System—MDM2—bone cancer	5.4e-05	0.00111	CbGpPWpGaD
Triazolam—GABRG2—Neuronal System—MDM2—bone cancer	5.3e-05	0.00109	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—NDUFA12—bone cancer	5.12e-05	0.00105	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—NT5C3A—bone cancer	4.9e-05	0.001	CbGpPWpGaD
Triazolam—GABRA1—Neuronal System—MDM2—bone cancer	4.64e-05	0.000949	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—NT5C3A—bone cancer	4.25e-05	0.00087	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—NDUFA12—bone cancer	4.17e-05	0.000854	CbGpPWpGaD
Triazolam—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.92e-05	0.000804	CbGpPWpGaD
Triazolam—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.87e-05	0.000793	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—NT5C3A—bone cancer	3.46e-05	0.000708	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—ENO2—bone cancer	2.97e-05	0.000608	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—DHFR—bone cancer	2.76e-05	0.000564	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—NDUFA12—bone cancer	2.75e-05	0.000563	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—GNA11—bone cancer	2.58e-05	0.000527	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—CYP3A4—bone cancer	2.34e-05	0.000478	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—NT5C3A—bone cancer	2.28e-05	0.000467	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—ENO2—bone cancer	2.15e-05	0.00044	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—GSTP1—bone cancer	2e-05	0.000409	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—DHFR—bone cancer	1.99e-05	0.000408	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—GNA11—bone cancer	1.86e-05	0.000381	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—ENO2—bone cancer	1.86e-05	0.000381	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—DHFR—bone cancer	1.73e-05	0.000353	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—CYP3A4—bone cancer	1.69e-05	0.000346	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—GNA11—bone cancer	1.61e-05	0.00033	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—ENO2—bone cancer	1.51e-05	0.00031	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—CYP3A4—bone cancer	1.46e-05	0.000299	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.45e-05	0.000298	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—GSTP1—bone cancer	1.44e-05	0.000296	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—DHFR—bone cancer	1.4e-05	0.000288	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—GNA11—bone cancer	1.31e-05	0.000269	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—GSTP1—bone cancer	1.25e-05	0.000256	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—CYP3A4—bone cancer	1.19e-05	0.000244	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.18e-05	0.000242	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—PTGS2—bone cancer	1.03e-05	0.000212	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—GSTP1—bone cancer	1.02e-05	0.000208	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—ENO2—bone cancer	9.98e-06	0.000204	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—DHFR—bone cancer	9.26e-06	0.00019	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—GNA11—bone cancer	8.66e-06	0.000177	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—PTGS2—bone cancer	7.48e-06	0.000153	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—GSTP1—bone cancer	6.71e-06	0.000137	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—PTGS2—bone cancer	6.48e-06	0.000133	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—PTGS2—bone cancer	5.27e-06	0.000108	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—PTGS2—bone cancer	3.48e-06	7.12e-05	CbGpPWpGaD
